Trial Profile

A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rozanolixizumab (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Adverse reactions; Proof of concept
Sponsors UCB

Most Recent Events

08 Sep 2020 According to an UCB media release, results from this study were published in the September online issue of Blood Advances.
08 Sep 2020 Results published in the UCB Media Release
10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com